Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $15 to $22.
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular RejectionCardiologists Performed the Fewes...
HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.
Raymond James analyst Andrew Cooper downgrades CareDx (NASDAQ:CDNA) from Outperform to Market Perform.
Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $10 to $14.
Stephens & Co. analyst Mason Carrico maintains CareDx (NASDAQ:CDNA) with a Overweight and raises the price target from $...
